Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial.
Saved in:
| Title: | Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial. |
|---|---|
| Authors: | Burris HA 3rd; Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN, USA. Electronic address: howard.burris@sarahcannon.com., Okusaka T; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan., Vogel A; Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany., Lee MA; Division of Medical Oncology, Department of Internal Medicine, Seoul St Mary's Hospital, Seoul, South Korea; College of Medicine, Catholic University of Korea, Seoul, South Korea., Takahashi H; Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan., Breder V; Department of Chemotherapy, N N Blokhin Russian Cancer Research Center, Moscow, Russia., Blanc JF; Department of Hepato-gastroenterology and Digestive Oncology, Hôpital Haut-Lévêque, Bordeaux, France., Li J; Department of Oncology, First Affiliated Hospital of Nanchang University, Nanchang, China., Bachini M; Cholangiocarcinoma Foundation, Herriman, UT, USA., Żotkiewicz M; AstraZeneca, Warsaw, Poland., Abraham J; Patient Centered Solutions, New York, NY, USA., Patel N; AstraZeneca, Gaithersburg, MD, USA., Wang J; AstraZeneca, Gaithersburg, MD, USA., Ali M; AstraZeneca, Gaithersburg, MD, USA., Rokutanda N; AstraZeneca, Gaithersburg, MD, USA., Cohen G; AstraZeneca, Gaithersburg, MD, USA., Oh DY; Division of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea. |
| Source: | The Lancet. Oncology [Lancet Oncol] 2024 May; Vol. 25 (5), pp. 626-635. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Research Support, Non-U.S. Gov't; Multicenter Study |
| Journal Info: | Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 38697156 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Burris+HA+3rd%22">Burris HA 3rd</searchLink>; Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN, USA. Electronic address: howard.burris@sarahcannon.com.<br /><searchLink fieldCode="AU" term="%22Okusaka+T%22">Okusaka T</searchLink>; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Vogel+A%22">Vogel A</searchLink>; Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.<br /><searchLink fieldCode="AU" term="%22Lee+MA%22">Lee MA</searchLink>; Division of Medical Oncology, Department of Internal Medicine, Seoul St Mary's Hospital, Seoul, South Korea; College of Medicine, Catholic University of Korea, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Takahashi+H%22">Takahashi H</searchLink>; Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.<br /><searchLink fieldCode="AU" term="%22Breder+V%22">Breder V</searchLink>; Department of Chemotherapy, N N Blokhin Russian Cancer Research Center, Moscow, Russia.<br /><searchLink fieldCode="AU" term="%22Blanc+JF%22">Blanc JF</searchLink>; Department of Hepato-gastroenterology and Digestive Oncology, Hôpital Haut-Lévêque, Bordeaux, France.<br /><searchLink fieldCode="AU" term="%22Li+J%22">Li J</searchLink>; Department of Oncology, First Affiliated Hospital of Nanchang University, Nanchang, China.<br /><searchLink fieldCode="AU" term="%22Bachini+M%22">Bachini M</searchLink>; Cholangiocarcinoma Foundation, Herriman, UT, USA.<br /><searchLink fieldCode="AU" term="%22Żotkiewicz+M%22">Żotkiewicz M</searchLink>; AstraZeneca, Warsaw, Poland.<br /><searchLink fieldCode="AU" term="%22Abraham+J%22">Abraham J</searchLink>; Patient Centered Solutions, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Patel+N%22">Patel N</searchLink>; AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Wang+J%22">Wang J</searchLink>; AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Ali+M%22">Ali M</searchLink>; AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Rokutanda+N%22">Rokutanda N</searchLink>; AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Cohen+G%22">Cohen G</searchLink>; AstraZeneca, Gaithersburg, MD, USA.<br /><searchLink fieldCode="AU" term="%22Oh+DY%22">Oh DY</searchLink>; Division of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22100957246%22">The Lancet. Oncology</searchLink> [Lancet Oncol] 2024 May; Vol. 25 (5), pp. 626-635. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Research Support, Non-U.S. Gov't; Multicenter Study – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Lancet+Pub%2E+Group%22">Lancet Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>100957246 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1474-5488 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214702045%22">14702045 </searchLink><i>NLM ISO Abbreviation: </i>Lancet Oncol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38697156 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/S1470-2045(24)00082-2 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 626 Titles: – TitleFull: Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Burris HA 3rd – PersonEntity: Name: NameFull: Okusaka T – PersonEntity: Name: NameFull: Vogel A – PersonEntity: Name: NameFull: Lee MA – PersonEntity: Name: NameFull: Takahashi H – PersonEntity: Name: NameFull: Breder V – PersonEntity: Name: NameFull: Blanc JF – PersonEntity: Name: NameFull: Li J – PersonEntity: Name: NameFull: Bachini M – PersonEntity: Name: NameFull: Żotkiewicz M – PersonEntity: Name: NameFull: Abraham J – PersonEntity: Name: NameFull: Patel N – PersonEntity: Name: NameFull: Wang J – PersonEntity: Name: NameFull: Ali M – PersonEntity: Name: NameFull: Rokutanda N – PersonEntity: Name: NameFull: Cohen G – PersonEntity: Name: NameFull: Oh DY IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 05 Text: 2024 May Type: published Y: 2024 Identifiers: – Type: issn-electronic Value: 1474-5488 Numbering: – Type: volume Value: 25 – Type: issue Value: 5 Titles: – TitleFull: The Lancet. Oncology Type: main |
| ResultId | 1 |
